Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS
Authors:
- Tariq KewanTKTariq Kewan
- Jan Philipp BewersdorfJBJan Philipp Bewersdorf
- Luca LaninoLLLuca Lanino
- Ondrej BlahaOBOndrej Blaha
- Jessica M. StempelJSJessica M. Stempel
- Najla H. Al AliNANajla H. Al Ali
- Amy E. DeZernADAmy E. DeZern
- Mikkael A. SekeresMSMikkael A. Sekeres
- Geoffrey L. UyGUGeoffrey L. Uy
- Samuel UrrutiaSUSamuel Urrutia
- Hetty E. CarrawayHCHetty E. Carraway
- Pinkal DesaiPDPinkal Desai
Open Access
- 14 November 2026
- journal article
- Published by Springer Nature in Blood Cancer Journal